SCHEMBL256345

SCHEMBL256345

Cn1ncc2ccncc21

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCNC P24863 4/20 0.40
CDK8 P49336 4/20 0.40
MAPT P10636 4/20 0.39
NFATC1 O95644 1/20 0.38
GSK3B P49841 1/20 0.38
DYRK1A Q13627 1/20 0.38
HASPIN Q8TF76 1/20 0.38
CYP19A1 P11511 1/20 0.37
NOTUM Q6P988 1/20 0.36
PDE10A Q9Y233 1/20 0.36
ATM Q13315 1/20 0.36
KCNH2 Q12809 1/20 0.36
AOC3 Q16853 1/20 0.36
TOP2A P11388 1/20 0.36
CDC7 O00311 1/20 0.36
TRPM5 Q9NZQ8 1/20 0.36
ERCC1 P07992 1/20 0.36
ERCC4 Q92889 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29958837 0.83 CDK8 (0.43) CCNCCDK8MAPTHASPINATM
SCHEMBL256359 0.83 CDK8 (0.43) CCNCCDK8MAPTHASPINATM
SCHEMBL29268041 0.74 CYP19A1 (0.37) MAPTCYP19A1PDE10AKCNH2AOC3
SCHEMBL16220608 0.74 CYP19A1 (0.37) MAPTCYP19A1PDE10AKCNH2AOC3
SCHEMBL30567622 0.74 CYP19A1 (0.37) MAPTCYP19A1PDE10AKCNH2AOC3
SCHEMBL21501930 0.74 HASPIN (0.49) MAPTHASPINCYP19A1NOTUMPDE10A
SCHEMBL29989046 0.74 HASPIN (0.49) MAPTHASPINCYP19A1NOTUMPDE10A
SCHEMBL17997563 0.74 DYRK1A (0.39) MAPTNFATC1GSK3BDYRK1AHASPIN
SCHEMBL12775610 0.74 CYP17A1 (0.41) MAPTNFATC1GSK3BDYRK1AHASPIN
SCHEMBL47226 0.73 CYP1A2 (0.47) CDK8MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INT (DE) 2026-03-19 US disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-4674415-A2 AZAQUINOLINES AS INHIBITORS OF CD38 Boehringer Ingelheim International GmbH (DE) 2026-01-07 EP disclosed
US-12398146-B2 Heterobicyclic amides as inhibitors of CD38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2025-08-26 US disclosed
EP-4284511-B1 AZAQUINOLINES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INT (DE) 2025-07-16 EP disclosed
CN-119431323-A Heterobicyclic amides as CD38 inhibitors 贝林格尔·英格海姆国际有限公司 2025-02-14 CN disclosed
US-20240368167-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-11-07 US disclosed
CN-114423753-B Heterobicyclic amides as CD38 inhibitors 里邦医疗公司 2024-09-17 CN disclosed
US-20240279224-A1 QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-08-22 US disclosed
US-11987584-B2 Heterobicyclic amides as inhibitors of CD38 BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2024-05-21 US disclosed
US-20120202776-A1 PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2012-08-09 US disclosed
WO-2012028332-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2012-03-08 WO disclosed
EP-2423208-A1 Pharmaceutically active compounds as Axl inhibitors Lead Discovery Center GmbH (DE) 2012-02-29 EP disclosed
WO-2011116951-A1 PHARMACEUTICALLY ACTIVE DISUBSTITUTED TRIAZINE DERIVATIVES LEAD DISCOVERY CENTER GMBH (DE) 2011-09-29 WO disclosed
US-20110059976-A1 PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS SUNESIS PHARMACEUTICALS, INC. 2011-03-10 US disclosed
US-7807684-B2 HIV reverse transcriptase inhibitors MERCK SHARP & DOHME CORP. (US) 2010-10-05 US disclosed
US-7767687-B2 Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors BIOGEN IDEC MA INC. (US) 2010-08-03 US disclosed
EP-2210881-A1 Derivatives of syringolin A Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2010-07-28 EP disclosed
WO-2010081731-A2 DERIVATIVES OF SYRINGOLIN A Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V (DE) 2010-07-22 WO disclosed
US-20070021442-A1 HIV reverse transcriptase inhibitors MERCK SHARP & DOHME CORP. 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368167-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 CD38, PARP12, ENTPD2 CCNC 66/4885CDK8 203/4885MAPT 4362/4885
US-12398146-B2 Heterobicyclic amides as inhibitors of CD38 CD38, PARP12, ENTPD2 CCNC 66/4885CDK8 203/4885MAPT 4362/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH CCNC 4138/4885CDK8 4037/4885MAPT 3782/4885
US-20240279224-A1 QUINOLINES AND AZAQUINOLINES AS INHIBITORS OF CD38 CD38, NQO1, NQO2 CCNC 164/4885CDK8 785/4885MAPT 4327/4885
US-20260078127-A1 HETEROBICYCLIC AMIDES AS INHIBITORS OF CD38 CD38, CD22, CD79B CCNC 63/4885CDK8 1018/4885MAPT 4832/4885
US-20070021442-A1 HIV reverse transcriptase inhibitors POLRMT, RNGTT, POLR2E CCNC 2797/4885CDK8 179/4885MAPT 620/4885
US-20120202776-A1 PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS PHKA1, PIK3CA, PHKA2 CCNC 741/4885CDK8 294/4885MAPT 3911/4885
US-11987584-B2 Heterobicyclic amides as inhibitors of CD38 CD38, PARP12, ENTPD2 CCNC 66/4885CDK8 203/4885MAPT 4362/4885
US-20110059976-A1 PYRIDO PYRIMIDINONES, DIHYDRO PYRIMIDO PYRIMIDINONES AND PTERIDINONES USEFUL AS RAF KINASE INHIBITORS BRAF, RAF1, ARAF CCNC 395/4885CDK8 46/4885MAPT 3486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.